The treatment of insulin resistance does not improve adrenal cytochrome P450c17α enzyme dysregulation in polycystic ovary syndrome

European Journal of Endocrinology

Volumn 140, Issue 1, 1999, Pages 56-61

  Ünlühizarci, Küŗad ^a   Keleştimur, Fahrettin ^a,b   Şahin, Yilmaz ^a   Bayram, Fahri ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b ERCIYES UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; CYTOCHROME P450 ISOENZYME; CYTOCHROME P450C17ALPHA; GLUCOSE; HYDROXYPROGESTERONE; INSULIN; METFORMIN; TESTOSTERONE; TETRACOSACTIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN TEST; FEMALE; HIRSUTISM; HORMONE RESPONSE; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; ERRATUM; ERROR;

17-ALPHA-HYDROXYPROGESTERONE; ADOLESCENT; ADRENAL GLANDS; ADRENOCORTICOTROPIC HORMONE; ADULT; ANDROSTENEDIONE; BLOOD GLUCOSE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; ISOENZYMES; METFORMIN; POLYCYSTIC OVARY SYNDROME;

EID: 0344609232     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1400056     Document Type: Article

References (34)

1. Franks S. Polycystic ovary syndrome. New England Journal of Medicine 1995 333 853-861
2. Chang JR, Nakamura RM, Judd HL & Kaplan SA. Insulin resistance in nonobese patients with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1983 57 356-359.
3. Nestler JE, Clore JN & Blackard WG. The central role of obesity (hyperinsulinemia) in the pathogenesis of the polycystic ovary syndrome. American Journal of Obstetrics and Gynecology 1989 161 1095-1097.
4. Barbieri RL, Smith S & Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertility and Sterility 1988 50 197-212.
5. Barnes RB, Rosenfield RL, Burstein S & Ehrmann DA. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. New England Journal of Medicine 1989 320 559-565.
6. Şahin Y & Keleştimur F. 17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome. Clinical Endocrinology 1993 39 151-155.
7. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF & Sheikh Z. Detection of functional ovarian hyperandrogenism in women with androgen excess. New England Journal of Medicine 1992 327 157-162.
8. Rosenfield RL, Barnes RB, Cara JF & Lucky AW. Dysregulation of cytochrome P450c17α as the cause of polycystic ovary syndrome. Fertility and Sterility 1990 53 785-791.
9. Nestler JE & Jakubowicz DJ. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New England Journal of Medicine 1996 335 617-623.
10. Velazquez EM, Mendoza S, Hamer T, Sosa F & Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia and systolic blood pressure while facilitating normal menses and pregnancy. Metabolism 1994 43 647-654.
11. Dunaif A, Scott D, Finegood D, Quintana B & Whitcomb R. The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1996 81 3299-3306.
12. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1997 82 2108-2116.
13. Scheen AJ. Drug treatment of non-insulin dependent diabetes mellitus in the 1990s. Drugs 1997 54 355-368.
14. Hatch R, Rosenfield RL, Kim MH & Tredway D. Hirsutism: implications, etiology and management. American Journal of Obstetrics and Gynecology 1981 140 815-830.
15. Adams J, Polson DW & Franks S. 1986 Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. British Medical Journal 1986 293 355-359.
16. Bonora E, Moghetti P, Zancanaro C, Cigolni M, Querena M, Cacyoton V et al. Estimates of in vivo insulin action in man: comparison of insulin tolerance test with euglycemic and hyperglycemic glucose clamp studies. Journal of Clinical Endocrinology and Metabolism 1989 68 374-378.
17. Ehrmann DA, Barnes R & Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocrine Reviews 1995 16 322-399.
18. Martikainen H, Salmela P, Nuojua-Huttunen S, Perala J, Leionen S, Knip M et al. Adrenal steroidogenesis is related to insulin in hyperandrogenic women. Fertility and Sterility 1996 66 564-570.
19. Turner EI, Watson MJ, Perry LA & White MC. Investigation of adrenal function in women with oligomenorrhoea and hirsutism (clinical PCOS) from the north-east of England using an adrenal stimulation test. Clinical Endocrinology 1992 36 389-397.
20. Şahin Y & Keleştimur F. 17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome P450c17α dysregulation. Human Reproduction 1997 12 910-913.
21. Keleştimur F, Şahin Y, Ayata D & Tutuş A. The prevalence of non-classic adrenal hyperplasia due to 110-hydroxylase deficiency among hirsute women in a Turkish population. Clinical Endocrinology 1996 45 381-384.
22. Azziz R, Rafi A, Smith BR, Bradley EL & Zacur HA. On the origin of the elevated 17-hydroxyprogesterone levels after adrenal stimulation in hyperandrogenism. Journal of Clinical Endocrinology and Metabolism 1990 70 431-436.
23. Rodin A, Thakkar H, Taylor N & Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. New England Journal of Medicine 1994 330 460-465.
24. Rosenfield RL. Evidence that idiopathic functional adrenal hyperandrogenism is caused by dysregulation of adrenal steroidogenesis and that hyperinsulinemia may be involved. Journal of Clinical Endocrinology and Metabolism 1996 81 878-880.
25. Ditkoff EC, Fruzzetti F, Chang L, Stancyzk FZ & Lobo RA. The impact of estrogen on adrenal androgen sensitivity and secretion in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1995 80 603-607.
26. Dunaif A, Segal KR, Futterweit W & Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989 38 1165-1174.
27. Kandarakis ED & Dunaif A. New perspectives in polycystic ovary syndrome. Trends in Endocrinology and Metabolism 1996 7267-271.
28. Şahin Y, Ayata D & Keleştimur F. Lack of relationship between 17-hydroxyprogesterone response to buserelin testing and hyper-insulinemia in polycystic ovary syndrome. European journal of Endocrinology 1997 136 410-41 5.
29. Crave JC, Fimbel S, Lejeune H, Cugnardey N, Dechaud H & Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens and insulin in hirsute and obese women. Journal of Clinical Endocrinology and Metabolism 1995 80 2057-2062.
30. Ehrmann DA, Cavaghan MS, Imperial J, Sturis J, Rosenfield R & Polonsky KS. Effects of metformin on insulin secretion, insulin action and ovarian steroidogenesis in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 1997 82 524-530.
31. Açbay Ö & Gündodu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertility and Sterility 1996 65 946-949.
32. Bailey CJ. Metformin and its role in the management of type II diabetes. Current Opinion in Endocrinology and Diabetes 1997 4 40-47.
33. Azziz R, Bradley ER, Potter DH & Boots LR. Adrenal androgen excess in women: lack of a role for 17-hydroxylase and 17,20-lyase dysregulation. Journal of Clinical Endocrinology and Metabolism 1995 80 400-405.
34. Moghetti P, Castello R, Negri C, Tosi F, Spiazzi GG, Brun E et al. Insulin infusion amplifies 17α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity Journal of Clinical Endocrinology and Metabolism 1996 81 881-886.